Key facts
- It has raised $11.6M; the latest was Later Stage VC in Jan 2026.
- Notable investors include SMBC Venture Capital, Nissay Capital, Keio Innovation Initiative, Chugai Pharmaceutical, DCI Partners — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for AdipoSeeds
- ·The full record, as it builds
Funding rounds
No funding rounds for AdipoSeeds are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AdipoSeeds
Developer of a platelet-making system designed to solve the shortage of platelets in the world and to create a future where a platelet-related treatment will be cheaply and safely provided. The company's platelet offers a novel technology for making platelets from mesenchymal stem cells without a complex and costly gene transfer along with a new blood supply system, enabling clients of the biotechnology industry with fat-derived platelets for blood products and wound care medicine.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2016
- Website
- adiposeeds.co.jp/
- Ownership
- Privately Held (backing)
AdipoSeeds doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AdipoSeeds shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AdipoSeeds in its N-PORT filings yet. We sweep new filings monthly.